Global Medical Cannabis Market

Medical Cannabis Comprehensive Study by Active Ingredients (Tetrahydrocannabinol {THC}, Cannabidiol {CBD}), Point of Sale (Dispensaries, Online Pharmacy, Hospital Pharmacy), Therapeutic Application (Pain, Arthritis, Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications}, Other) Players and Region - Global Market Outlook to 2030

Medical Cannabis Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 24.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Medicinal cannabis is also known as Medical marijuana, which is used either to treat disease or to improve their symptoms. The two cannabinoids such as delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) are used in the treatment of a certain disease or health conditions such as pain, memory, blood pressure, concentration, appetite, sensory stimulus, muscular problems, and seizures. The numerous economies are involved in the activities to legalize the export of medicinal cannabis product, which in turn is expected to fuel the growth of the medical cannabis market. According to AMA Research, the market for Medical Cannabis is expected to register a CAGR of 24.5% during the forecast period to 2030. This growth is primarily driven by Expansion Of Medicinal Cannabis Product By Various Manufacturers .

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitKilo Tons
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as BOL Pharma (Israel), Tilray (Canada), Medreleaf Corporation (Canada), Aurora Cannabis, Inc. (Canada), Canopy Growth Corporation (Canada), Insys Therapeutics, Inc. (United States), Aphria, Inc. (Canada), MGC Pharmaceuticals Limited (Australia), GW Pharmaceuticals, plc (United Kingdom) and Medical Marijuana Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 22 Jan 2019, Tilray, Inc. has announced a definitive agreement with Natura Naturals Holdings Inc., the parent company of a licensed cultivator of cannabis. Due to the agreement, Tilray will obtain Natura’s 662,000 square-foot greenhouse cultivation facility, of which 155,000 square-feet are currently licensed, and all subsequent cannabis output from this facility. and On 19 March 2018, MedReleaf Corp., Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, has announced that it has entered into an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH, a leading medical cannabis distributor to pharmacies in Germany.
On 21 Jan. 2019, Canopy Growth Corporation has announced the expansion of its business in the European regions such as the United Kingdom and Poland where its medically-focused business Spectrum Cannabis continues to build a sophisticated, pan-European cannabis production as well as distribution network serving the needs of physicians and their patients throughout the continent. and On 9 Oct. 2018, Canopy Growth Corporation has completed a legal transfer of cannabis products to a research partner in the United States. This transfer is the initial export of legal cannabis products from Canada to the United States pursuant to an import permit issued by the federal United States Drug Enforcement Administration.Key players are adopting numerous strategies to gain market attention and to increase their market share, this strategy can be listed as increasing product portfolio, making partnerships to adopt certain technologies, and acquiring small players to finish the competition in the future. As well as investing money in the R&D sector to make technical upgrades to the product.

Regulatory Insights:
On January 16, 2019, California’s three state cannabis licensing authorities have announced that the Office of Administrative Law (OAL) officially approved state regulations for cannabis businesses across the supply chain.

Influencing Trend:
The launch of New Cannabis Consumer Products, Transition to Adult-Use Cannabis and Health Safety in Cannabis Products

Market Growth Drivers:
Expansion Of Medicinal Cannabis Product By Various Manufacturers, Legalization Of Medicinal Cannabis In Various Economies, Rising geriatric population in need of treatment for chronic diseases and Increasing Research And Development Activities

Challenges:
Excessive consumption Leads to The Risk of Heart Attack

Restraints:
Stringent FDA and other regulations

Opportunities:
Emerging Demand From Economies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Medical Cannabis Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Medical Cannabis Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Medical Cannabis players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Medical Cannabis Study Sheds Light on
— The Medical Cannabis Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Medical Cannabis industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Medical Cannabis industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Active Ingredients
  • Tetrahydrocannabinol {THC}
  • Cannabidiol {CBD}

By Point of Sale
  • Dispensaries
  • Online Pharmacy
  • Hospital Pharmacy

By Therapeutic Application
  • Pain
  • Arthritis
  • Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications}
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Expansion Of Medicinal Cannabis Product By Various Manufacturers
      • 3.2.2. Legalization Of Medicinal Cannabis In Various Economies
      • 3.2.3. Rising geriatric population in need of treatment for chronic diseases
      • 3.2.4. Increasing Research And Development Activities
    • 3.3. Market Challenges
      • 3.3.1. Excessive consumption Leads to The Risk of Heart Attack
    • 3.4. Market Trends
      • 3.4.1. The launch of New Cannabis Consumer Products
      • 3.4.2. Transition to Adult-Use Cannabis
      • 3.4.3. Health Safety in Cannabis Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Medical Cannabis, by Active Ingredients, Point of Sale, Therapeutic Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Medical Cannabis (Value)
      • 5.2.1. Global Medical Cannabis by: Active Ingredients (Value)
        • 5.2.1.1. Tetrahydrocannabinol {THC}
        • 5.2.1.2. Cannabidiol {CBD}
      • 5.2.2. Global Medical Cannabis by: Point of Sale (Value)
        • 5.2.2.1. Dispensaries
        • 5.2.2.2. Online Pharmacy
        • 5.2.2.3. Hospital Pharmacy
      • 5.2.3. Global Medical Cannabis by: Therapeutic Application (Value)
        • 5.2.3.1. Pain
        • 5.2.3.2. Arthritis
        • 5.2.3.3. Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications}
        • 5.2.3.4. Other
      • 5.2.4. Global Medical Cannabis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Medical Cannabis (Volume)
      • 5.3.1. Global Medical Cannabis by: Active Ingredients (Volume)
        • 5.3.1.1. Tetrahydrocannabinol {THC}
        • 5.3.1.2. Cannabidiol {CBD}
      • 5.3.2. Global Medical Cannabis by: Point of Sale (Volume)
        • 5.3.2.1. Dispensaries
        • 5.3.2.2. Online Pharmacy
        • 5.3.2.3. Hospital Pharmacy
      • 5.3.3. Global Medical Cannabis by: Therapeutic Application (Volume)
        • 5.3.3.1. Pain
        • 5.3.3.2. Arthritis
        • 5.3.3.3. Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications}
        • 5.3.3.4. Other
      • 5.3.4. Global Medical Cannabis Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Medical Cannabis (Price)
  • 6. Medical Cannabis: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. BOL Pharma (Israel)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Tilray (Canada)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. Medreleaf Corporation (Canada)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Aurora Cannabis, Inc. (Canada)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Canopy Growth Corporation (Canada)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Insys Therapeutics, Inc. (United States)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Aphria, Inc. (Canada)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. MGC Pharmaceuticals Limited (Australia)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. GW Pharmaceuticals, plc (United Kingdom)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Medical Marijuana Inc. (United States)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Medical Cannabis Sale, by Active Ingredients, Point of Sale, Therapeutic Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Medical Cannabis (Value)
      • 7.2.1. Global Medical Cannabis by: Active Ingredients (Value)
        • 7.2.1.1. Tetrahydrocannabinol {THC}
        • 7.2.1.2. Cannabidiol {CBD}
      • 7.2.2. Global Medical Cannabis by: Point of Sale (Value)
        • 7.2.2.1. Dispensaries
        • 7.2.2.2. Online Pharmacy
        • 7.2.2.3. Hospital Pharmacy
      • 7.2.3. Global Medical Cannabis by: Therapeutic Application (Value)
        • 7.2.3.1. Pain
        • 7.2.3.2. Arthritis
        • 7.2.3.3. Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications}
        • 7.2.3.4. Other
      • 7.2.4. Global Medical Cannabis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Medical Cannabis (Volume)
      • 7.3.1. Global Medical Cannabis by: Active Ingredients (Volume)
        • 7.3.1.1. Tetrahydrocannabinol {THC}
        • 7.3.1.2. Cannabidiol {CBD}
      • 7.3.2. Global Medical Cannabis by: Point of Sale (Volume)
        • 7.3.2.1. Dispensaries
        • 7.3.2.2. Online Pharmacy
        • 7.3.2.3. Hospital Pharmacy
      • 7.3.3. Global Medical Cannabis by: Therapeutic Application (Volume)
        • 7.3.3.1. Pain
        • 7.3.3.2. Arthritis
        • 7.3.3.3. Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications}
        • 7.3.3.4. Other
      • 7.3.4. Global Medical Cannabis Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Medical Cannabis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Medical Cannabis: by Active Ingredients(USD Million)
  • Table 2. Medical Cannabis Tetrahydrocannabinol {THC} , by Region USD Million (2018-2023)
  • Table 3. Medical Cannabis Cannabidiol {CBD} , by Region USD Million (2018-2023)
  • Table 4. Medical Cannabis: by Point of Sale(USD Million)
  • Table 5. Medical Cannabis Dispensaries , by Region USD Million (2018-2023)
  • Table 6. Medical Cannabis Online Pharmacy , by Region USD Million (2018-2023)
  • Table 7. Medical Cannabis Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Medical Cannabis: by Therapeutic Application(USD Million)
  • Table 9. Medical Cannabis Pain , by Region USD Million (2018-2023)
  • Table 10. Medical Cannabis Arthritis , by Region USD Million (2018-2023)
  • Table 11. Medical Cannabis Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications} , by Region USD Million (2018-2023)
  • Table 12. Medical Cannabis Other , by Region USD Million (2018-2023)
  • Table 13. South America Medical Cannabis, by Country USD Million (2018-2023)
  • Table 14. South America Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 15. South America Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 16. South America Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 17. Brazil Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 18. Brazil Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 19. Brazil Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 20. Argentina Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 21. Argentina Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 22. Argentina Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 23. Rest of South America Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 24. Rest of South America Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 25. Rest of South America Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 26. Asia Pacific Medical Cannabis, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 28. Asia Pacific Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 29. Asia Pacific Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 30. China Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 31. China Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 32. China Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 33. Japan Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 34. Japan Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 35. Japan Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 36. India Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 37. India Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 38. India Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 39. South Korea Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 40. South Korea Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 41. South Korea Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 42. Taiwan Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 43. Taiwan Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 44. Taiwan Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 45. Australia Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 46. Australia Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 47. Australia Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 51. Europe Medical Cannabis, by Country USD Million (2018-2023)
  • Table 52. Europe Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 53. Europe Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 54. Europe Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 55. Germany Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 56. Germany Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 57. Germany Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 58. France Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 59. France Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 60. France Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 61. Italy Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 62. Italy Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 63. Italy Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 64. United Kingdom Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 65. United Kingdom Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 66. United Kingdom Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 67. Netherlands Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 68. Netherlands Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 69. Netherlands Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 70. Rest of Europe Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 71. Rest of Europe Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 72. Rest of Europe Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 73. MEA Medical Cannabis, by Country USD Million (2018-2023)
  • Table 74. MEA Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 75. MEA Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 76. MEA Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 77. Middle East Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 78. Middle East Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 79. Middle East Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 80. Africa Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 81. Africa Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 82. Africa Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 83. North America Medical Cannabis, by Country USD Million (2018-2023)
  • Table 84. North America Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 85. North America Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 86. North America Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 87. United States Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 88. United States Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 89. United States Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 90. Canada Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 91. Canada Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 92. Canada Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 93. Mexico Medical Cannabis, by Active Ingredients USD Million (2018-2023)
  • Table 94. Mexico Medical Cannabis, by Point of Sale USD Million (2018-2023)
  • Table 95. Mexico Medical Cannabis, by Therapeutic Application USD Million (2018-2023)
  • Table 96. Medical Cannabis Sales: by Active Ingredients(Kilo Tons)
  • Table 97. Medical Cannabis Sales Tetrahydrocannabinol {THC} , by Region Kilo Tons (2018-2023)
  • Table 98. Medical Cannabis Sales Cannabidiol {CBD} , by Region Kilo Tons (2018-2023)
  • Table 99. Medical Cannabis Sales: by Point of Sale(Kilo Tons)
  • Table 100. Medical Cannabis Sales Dispensaries , by Region Kilo Tons (2018-2023)
  • Table 101. Medical Cannabis Sales Online Pharmacy , by Region Kilo Tons (2018-2023)
  • Table 102. Medical Cannabis Sales Hospital Pharmacy , by Region Kilo Tons (2018-2023)
  • Table 103. Medical Cannabis Sales: by Therapeutic Application(Kilo Tons)
  • Table 104. Medical Cannabis Sales Pain , by Region Kilo Tons (2018-2023)
  • Table 105. Medical Cannabis Sales Arthritis , by Region Kilo Tons (2018-2023)
  • Table 106. Medical Cannabis Sales Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications} , by Region Kilo Tons (2018-2023)
  • Table 107. Medical Cannabis Sales Other , by Region Kilo Tons (2018-2023)
  • Table 108. South America Medical Cannabis Sales, by Country Kilo Tons (2018-2023)
  • Table 109. South America Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 110. South America Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 111. South America Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 112. Brazil Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 113. Brazil Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 114. Brazil Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 115. Argentina Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 116. Argentina Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 117. Argentina Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 118. Rest of South America Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 119. Rest of South America Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 120. Rest of South America Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 121. Asia Pacific Medical Cannabis Sales, by Country Kilo Tons (2018-2023)
  • Table 122. Asia Pacific Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 123. Asia Pacific Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 124. Asia Pacific Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 125. China Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 126. China Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 127. China Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 128. Japan Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 129. Japan Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 130. Japan Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 131. India Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 132. India Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 133. India Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 134. South Korea Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 135. South Korea Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 136. South Korea Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 137. Taiwan Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 138. Taiwan Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 139. Taiwan Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 140. Australia Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 141. Australia Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 142. Australia Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 143. Rest of Asia-Pacific Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 144. Rest of Asia-Pacific Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 145. Rest of Asia-Pacific Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 146. Europe Medical Cannabis Sales, by Country Kilo Tons (2018-2023)
  • Table 147. Europe Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 148. Europe Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 149. Europe Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 150. Germany Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 151. Germany Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 152. Germany Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 153. France Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 154. France Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 155. France Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 156. Italy Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 157. Italy Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 158. Italy Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 159. United Kingdom Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 160. United Kingdom Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 161. United Kingdom Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 162. Netherlands Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 163. Netherlands Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 164. Netherlands Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 165. Rest of Europe Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 166. Rest of Europe Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 167. Rest of Europe Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 168. MEA Medical Cannabis Sales, by Country Kilo Tons (2018-2023)
  • Table 169. MEA Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 170. MEA Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 171. MEA Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 172. Middle East Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 173. Middle East Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 174. Middle East Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 175. Africa Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 176. Africa Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 177. Africa Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 178. North America Medical Cannabis Sales, by Country Kilo Tons (2018-2023)
  • Table 179. North America Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 180. North America Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 181. North America Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 182. United States Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 183. United States Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 184. United States Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 185. Canada Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 186. Canada Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 187. Canada Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 188. Mexico Medical Cannabis Sales, by Active Ingredients Kilo Tons (2018-2023)
  • Table 189. Mexico Medical Cannabis Sales, by Point of Sale Kilo Tons (2018-2023)
  • Table 190. Mexico Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2018-2023)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Medical Cannabis: by Active Ingredients(USD Million)
  • Table 202. Medical Cannabis Tetrahydrocannabinol {THC} , by Region USD Million (2025-2030)
  • Table 203. Medical Cannabis Cannabidiol {CBD} , by Region USD Million (2025-2030)
  • Table 204. Medical Cannabis: by Point of Sale(USD Million)
  • Table 205. Medical Cannabis Dispensaries , by Region USD Million (2025-2030)
  • Table 206. Medical Cannabis Online Pharmacy , by Region USD Million (2025-2030)
  • Table 207. Medical Cannabis Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 208. Medical Cannabis: by Therapeutic Application(USD Million)
  • Table 209. Medical Cannabis Pain , by Region USD Million (2025-2030)
  • Table 210. Medical Cannabis Arthritis , by Region USD Million (2025-2030)
  • Table 211. Medical Cannabis Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications} , by Region USD Million (2025-2030)
  • Table 212. Medical Cannabis Other , by Region USD Million (2025-2030)
  • Table 213. South America Medical Cannabis, by Country USD Million (2025-2030)
  • Table 214. South America Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 215. South America Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 216. South America Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 217. Brazil Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 218. Brazil Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 219. Brazil Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 220. Argentina Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 221. Argentina Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 222. Argentina Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 223. Rest of South America Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 224. Rest of South America Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 225. Rest of South America Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 226. Asia Pacific Medical Cannabis, by Country USD Million (2025-2030)
  • Table 227. Asia Pacific Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 228. Asia Pacific Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 229. Asia Pacific Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 230. China Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 231. China Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 232. China Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 233. Japan Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 234. Japan Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 235. Japan Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 236. India Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 237. India Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 238. India Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 239. South Korea Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 240. South Korea Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 241. South Korea Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 242. Taiwan Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 243. Taiwan Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 244. Taiwan Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 245. Australia Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 246. Australia Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 247. Australia Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 249. Rest of Asia-Pacific Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 250. Rest of Asia-Pacific Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 251. Europe Medical Cannabis, by Country USD Million (2025-2030)
  • Table 252. Europe Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 253. Europe Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 254. Europe Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 255. Germany Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 256. Germany Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 257. Germany Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 258. France Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 259. France Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 260. France Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 261. Italy Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 262. Italy Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 263. Italy Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 264. United Kingdom Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 265. United Kingdom Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 266. United Kingdom Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 267. Netherlands Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 268. Netherlands Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 269. Netherlands Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 270. Rest of Europe Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 271. Rest of Europe Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 272. Rest of Europe Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 273. MEA Medical Cannabis, by Country USD Million (2025-2030)
  • Table 274. MEA Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 275. MEA Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 276. MEA Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 277. Middle East Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 278. Middle East Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 279. Middle East Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 280. Africa Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 281. Africa Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 282. Africa Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 283. North America Medical Cannabis, by Country USD Million (2025-2030)
  • Table 284. North America Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 285. North America Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 286. North America Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 287. United States Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 288. United States Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 289. United States Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 290. Canada Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 291. Canada Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 292. Canada Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 293. Mexico Medical Cannabis, by Active Ingredients USD Million (2025-2030)
  • Table 294. Mexico Medical Cannabis, by Point of Sale USD Million (2025-2030)
  • Table 295. Mexico Medical Cannabis, by Therapeutic Application USD Million (2025-2030)
  • Table 296. Medical Cannabis Sales: by Active Ingredients(Kilo Tons)
  • Table 297. Medical Cannabis Sales Tetrahydrocannabinol {THC} , by Region Kilo Tons (2025-2030)
  • Table 298. Medical Cannabis Sales Cannabidiol {CBD} , by Region Kilo Tons (2025-2030)
  • Table 299. Medical Cannabis Sales: by Point of Sale(Kilo Tons)
  • Table 300. Medical Cannabis Sales Dispensaries , by Region Kilo Tons (2025-2030)
  • Table 301. Medical Cannabis Sales Online Pharmacy , by Region Kilo Tons (2025-2030)
  • Table 302. Medical Cannabis Sales Hospital Pharmacy , by Region Kilo Tons (2025-2030)
  • Table 303. Medical Cannabis Sales: by Therapeutic Application(Kilo Tons)
  • Table 304. Medical Cannabis Sales Pain , by Region Kilo Tons (2025-2030)
  • Table 305. Medical Cannabis Sales Arthritis , by Region Kilo Tons (2025-2030)
  • Table 306. Medical Cannabis Sales Neurological Disease {Epilepsy, Multiple Sclerosis, and Other Neurological Applications} , by Region Kilo Tons (2025-2030)
  • Table 307. Medical Cannabis Sales Other , by Region Kilo Tons (2025-2030)
  • Table 308. South America Medical Cannabis Sales, by Country Kilo Tons (2025-2030)
  • Table 309. South America Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 310. South America Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 311. South America Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 312. Brazil Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 313. Brazil Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 314. Brazil Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 315. Argentina Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 316. Argentina Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 317. Argentina Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 318. Rest of South America Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 319. Rest of South America Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 320. Rest of South America Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 321. Asia Pacific Medical Cannabis Sales, by Country Kilo Tons (2025-2030)
  • Table 322. Asia Pacific Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 323. Asia Pacific Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 324. Asia Pacific Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 325. China Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 326. China Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 327. China Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 328. Japan Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 329. Japan Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 330. Japan Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 331. India Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 332. India Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 333. India Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 334. South Korea Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 335. South Korea Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 336. South Korea Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 337. Taiwan Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 338. Taiwan Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 339. Taiwan Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 340. Australia Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 341. Australia Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 342. Australia Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 343. Rest of Asia-Pacific Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 344. Rest of Asia-Pacific Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 345. Rest of Asia-Pacific Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 346. Europe Medical Cannabis Sales, by Country Kilo Tons (2025-2030)
  • Table 347. Europe Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 348. Europe Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 349. Europe Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 350. Germany Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 351. Germany Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 352. Germany Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 353. France Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 354. France Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 355. France Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 356. Italy Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 357. Italy Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 358. Italy Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 359. United Kingdom Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 360. United Kingdom Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 361. United Kingdom Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 362. Netherlands Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 363. Netherlands Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 364. Netherlands Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 365. Rest of Europe Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 366. Rest of Europe Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 367. Rest of Europe Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 368. MEA Medical Cannabis Sales, by Country Kilo Tons (2025-2030)
  • Table 369. MEA Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 370. MEA Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 371. MEA Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 372. Middle East Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 373. Middle East Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 374. Middle East Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 375. Africa Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 376. Africa Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 377. Africa Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 378. North America Medical Cannabis Sales, by Country Kilo Tons (2025-2030)
  • Table 379. North America Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 380. North America Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 381. North America Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 382. United States Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 383. United States Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 384. United States Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 385. Canada Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 386. Canada Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 387. Canada Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 388. Mexico Medical Cannabis Sales, by Active Ingredients Kilo Tons (2025-2030)
  • Table 389. Mexico Medical Cannabis Sales, by Point of Sale Kilo Tons (2025-2030)
  • Table 390. Mexico Medical Cannabis Sales, by Therapeutic Application Kilo Tons (2025-2030)
  • Table 391. Research Programs/Design for This Report
  • Table 392. Key Data Information from Secondary Sources
  • Table 393. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Medical Cannabis: by Active Ingredients USD Million (2018-2023)
  • Figure 5. Global Medical Cannabis: by Point of Sale USD Million (2018-2023)
  • Figure 6. Global Medical Cannabis: by Therapeutic Application USD Million (2018-2023)
  • Figure 7. South America Medical Cannabis Share (%), by Country
  • Figure 8. Asia Pacific Medical Cannabis Share (%), by Country
  • Figure 9. Europe Medical Cannabis Share (%), by Country
  • Figure 10. MEA Medical Cannabis Share (%), by Country
  • Figure 11. North America Medical Cannabis Share (%), by Country
  • Figure 12. Global Medical Cannabis: by Active Ingredients Kilo Tons (2018-2023)
  • Figure 13. Global Medical Cannabis: by Point of Sale Kilo Tons (2018-2023)
  • Figure 14. Global Medical Cannabis: by Therapeutic Application Kilo Tons (2018-2023)
  • Figure 15. South America Medical Cannabis Share (%), by Country
  • Figure 16. Asia Pacific Medical Cannabis Share (%), by Country
  • Figure 17. Europe Medical Cannabis Share (%), by Country
  • Figure 18. MEA Medical Cannabis Share (%), by Country
  • Figure 19. North America Medical Cannabis Share (%), by Country
  • Figure 20. BOL Pharma (Israel) Revenue, Net Income and Gross profit
  • Figure 21. BOL Pharma (Israel) Revenue: by Geography 2023
  • Figure 22. Tilray (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Tilray (Canada) Revenue: by Geography 2023
  • Figure 24. Medreleaf Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Medreleaf Corporation (Canada) Revenue: by Geography 2023
  • Figure 26. Aurora Cannabis, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Aurora Cannabis, Inc. (Canada) Revenue: by Geography 2023
  • Figure 28. Canopy Growth Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Canopy Growth Corporation (Canada) Revenue: by Geography 2023
  • Figure 30. Insys Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Insys Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Aphria, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 33. Aphria, Inc. (Canada) Revenue: by Geography 2023
  • Figure 34. MGC Pharmaceuticals Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 35. MGC Pharmaceuticals Limited (Australia) Revenue: by Geography 2023
  • Figure 36. GW Pharmaceuticals, plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GW Pharmaceuticals, plc (United Kingdom) Revenue: by Geography 2023
  • Figure 38. Medical Marijuana Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Medical Marijuana Inc. (United States) Revenue: by Geography 2023
  • Figure 40. Global Medical Cannabis: by Active Ingredients USD Million (2025-2030)
  • Figure 41. Global Medical Cannabis: by Point of Sale USD Million (2025-2030)
  • Figure 42. Global Medical Cannabis: by Therapeutic Application USD Million (2025-2030)
  • Figure 43. South America Medical Cannabis Share (%), by Country
  • Figure 44. Asia Pacific Medical Cannabis Share (%), by Country
  • Figure 45. Europe Medical Cannabis Share (%), by Country
  • Figure 46. MEA Medical Cannabis Share (%), by Country
  • Figure 47. North America Medical Cannabis Share (%), by Country
  • Figure 48. Global Medical Cannabis: by Active Ingredients Kilo Tons (2025-2030)
  • Figure 49. Global Medical Cannabis: by Point of Sale Kilo Tons (2025-2030)
  • Figure 50. Global Medical Cannabis: by Therapeutic Application Kilo Tons (2025-2030)
  • Figure 51. South America Medical Cannabis Share (%), by Country
  • Figure 52. Asia Pacific Medical Cannabis Share (%), by Country
  • Figure 53. Europe Medical Cannabis Share (%), by Country
  • Figure 54. MEA Medical Cannabis Share (%), by Country
  • Figure 55. North America Medical Cannabis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • BOL Pharma (Israel)
  • Tilray (Canada)
  • Medreleaf Corporation (Canada)
  • Aurora Cannabis, Inc. (Canada)
  • Canopy Growth Corporation (Canada)
  • Insys Therapeutics, Inc. (United States)
  • Aphria, Inc. (Canada)
  • MGC Pharmaceuticals Limited (Australia)
  • GW Pharmaceuticals, plc (United Kingdom)
  • Medical Marijuana Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 210 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Medical Cannabis Market Quantitative research analysis
Global Medical Cannabis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global Medical Cannabis Market are BOL Pharma (Israel), Tilray (Canada), Medreleaf Corporation (Canada), Aurora Cannabis, Inc. (Canada), Canopy Growth Corporation (Canada), Insys Therapeutics, Inc. (United States), Aphria, Inc. (Canada), MGC Pharmaceuticals Limited (Australia), GW Pharmaceuticals, plc (United Kingdom) and Medical Marijuana Inc. (United States) etc.
AMA Research predicts that Canadian Players will contribute to the maximum growth of Global Medical Cannabis market throughout the forecasted period.

Know More About Global Medical Cannabis Market Report?

Have a Query? Click Here

Other Related Reports

Dementia Drugs Comprehensive Study by Type (MAO Inhibitors, Cholinesterase Inhibitors, Glutamate Inhibitors), Application (Hospital, Clinics, Others), Indication (Lewy Body Dementia, Parkinsons Disea...
$ 3650
Liposome Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphotericin B, Liposomal Paclitaxel), Application (Pharmaceutical, Cosmetic, Food, Farming), Therapy (Fungal Infe...
$ 3350
Anti-infective Agents Comprehensive Study by Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Application (Hospital Use, Clinic Use, Household, Other), Drug Type (Penicillins, Sulfonami...
$ 3750
Legal Marijuana Comprehensive Study by Type (Indoor, Greenhouse), Application (Chronic Pain, Mental Disorders, Cancer, Others), End-Users (Healthcare Industry, Recreational Industry, Others) Players ...
$ 3500
Veterinary Drugs Comprehensive Study by Type (Antibiotics, Non-Steroidal Anti-Inflammatories, Steroids, Opioid Pain Relievers, Anti-Parasitics, Behavior-Modifying Drugs and Sedatives, Hormones, Chemo...
$ 3750
Divalproex Sodium Comprehensive Study by Type (Tablet, Capsule, Others), Application (Epilepsy, Manic-Depressive Illness, Migraine Prophylaxis, Other), Sales Channel (Hospital Pharmacies, Online Phar...
$ 3450